Logo
Logo

About Pantoprazole Sodium API

Product
  • Therapeutic CategoryGastro-Intestinal - GI

  • CAS Number

    164579-32-2

  • API Technology

    Synthetic

  • Dose Form

    Suspension, Tablets, Injectable

  • Dr Reddy's Development Status

    Available

  • Available Regulatory Filing

    USDMF, CEP Submitted, Brazil DMF, EUDMF, Canada DMF, Japan DMF, China DMF

Mechanism of Action

Pantoprazole is a PPI that suppresses the final step in gastric acid production by covalently binding to the (H+, K+)-ATPase enzyme system at the secretory surface of the gastric parietal cell. This effect leads to inhibition of both basal and stimulated gastric acid secretion, irrespective of the stimulus. The binding to the (H+, K+)-ATPase results in a duration of antisecretory effect that persists longer than 24 hours for all doses tested (20 mg to 120 mg).

Indication

PROTONIX is a proton pump inhibitor (PPI) indicated for the following:

  • Short-Term Treatment of Erosive Esophagitis Associated with Gastroesophageal Reflux Disease (GERD)
  • Maintenance of Healing of Erosive Esophagitis
  • Pathological Hypersecretory Conditions Including Zollinger-Ellison (ZE) Syndrome

Related APIs

Esomeprazole Magnesium Trihydrate

Gastro-Intestinal - GI

arrow

Famotidine

Gastro-Intestinal - GI

arrow

Lubiprostone

Gastro-Intestinal - GI

arrow

Nizatidine

Gastro-Intestinal - GI

arrow

Omeprazole

Gastro-Intestinal - GI

arrow

Omeprazole Magnesium

Gastro-Intestinal - GI

arrow

Pantoprazole Sodium

Gastro-Intestinal - GI

arrow

Rabeprazole Sodium (Amorphous & Form Y)

Gastro-Intestinal - GI

arrow

Vonoprazan Fumarate

Gastro-Intestinal - GI

arrow

Request for Quotation

Get in touch with us by filling out the form below. Our team will reach out to you shortly!

Phone
Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act (Bolar Exemption) and not for commercial sale.